Intravenous immunoglobulins in the prevention of infection in children with hematologic-oncologic diseases.

Treatment with intensive myelosuppressive therapy results in decreased leve ls of immunoglobulins. Whereas pediatric cancer patients undergoing chemoth erapy do not benefit from the routine administration of intravenous immunog lobulins, prophylactic intravenous immunoglobulins given after bone marrow transplantation or after peripheral stem cell transplantation reduce infect ious complications. Still, prospective clinical trials are needed to define specific treatment groups who can benefit from immunoglobulin support. In addition, randomized studies are required to evaluate the proper dosage and duration of therapy. Passive immunization of children potentially incubate d with varicella or measles is generally recommended.